Aurisco, a pharmaceutical company and contract development and manufacturing organization (CDMO) in China, is cooperating with global life sciences company Cytiva, to build its first Oligo FlexFactory platform for commercial production.
The Oligo FlexFactory platform is the first of the three planned commercial manufacturing lines of Aurisco in Yangzhou of East China. The entire manufacturing site is expected to produce 200 kilograms of oligonucleotides every year.
Oligonucleotides are synthetic strands of DNA or RNA that can be used as therapies and diagnostics by binding to a target gene or protein sequence. Oligonucleotide therapeutics, including siRNA (small interfering RNA) and ASO (antisense oligonucleotide), hold promise in treating cancers, Parkinson’s diseases, and various other conditions. The global oligonucleotide synthesis market is expected to reach $16.7 billion by 2027, according to Research and Markets.
“Aurisco is committed into continuous technological innovation that will help our customers deliver better and safer medicines to patients around the world,” said Peng Zhi’en, chairman of Aurisco. “I believe the cooperation with Cytiva will facilitate our mission by bringing better speed and efficiency to the commercial production of oligonucleotides.”
During this cooperation, Cytiva will offer a comprehensive enterprise solution to Aurisco. It includes an Oligo FlexFactory GMP platform and various technical and service support, such as talent training, process design of the manufacturing site, as well as life-cycle project management.
It’s not the first time Aurisco has collaborated with Cytiva. Previously, with the support of Cytiva’s products and service, Aurisco has launched oligonucleotide CRO (contract research organization) and CDMO services of laboratory and pilot scales in Shanghai.
